Table 1 Drugs targeting candidate epigenes from modules 4, 6, 8, and 10–12.
From: Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection
Target protein | Drug name | Module | Function |
|---|---|---|---|
TOP2A | Genistein, fluorouracil, intoplicine, enoxacin, sparfloxacin, amrubicin, etoposide, epirubicin, ciprofloxacin, myricetin, mitoxantrone, trovafloxacin, RTA 744, daunorubicin, norfloxacin, finafloxacin, dexrazoxane, 13-deoxydoxorubicin, idarubicin, lomefloxacin, lucanthone, pefloxacin, valrubicin, amsacrine, levofloxacin, doxorubicin, declopramide, annamycin, banoxantrone, ZEN-012, podofilox, aldoxorubicin, teniposide, moxifloxacin, SP1049C, amonafide, dactinomycin, fleroxacin, becatecarin, ofloxacin, and elsamitrucin | Module 8 | Epifactor (chromatin remodeling) |
BRD4 | Fedratinib, panobinostat, romidepsin, birabresib, alprazolam, vorinostat, volasertib, alobresib, belinostat, and apabetalone | Module 6 | Epifactor (histone modification read) |
EP300 | Curcumin | Module 6 | Epifactor (histone modification write) |
DNMT1 | S-adenosyl-L-homocysteine, procainamide, palifosfamide, cefalotin, decitabine, azacitidine, flucytosine, epigallocatechin gallate, and hydralazine | Module 4 | Epifactor (DNA methylation) |
SENP3 | Methylphenidate | Module 4 | Epifactor (histone modification erase, histone modification write cofactor) |
SIRT6 | 7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide | Module 4 | Epifactor (histone modification erase) |
FOS | Pseudoephedrine and nadroparin | Module 12 | TF |
RELA | SC-236, betulinic acid, bortezomib, dimethyl fumarate, PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-thiazole, indoprofen | Module 12 | TF |
STAT1 | Epigallocatechin gallate | Module 12 | TF |
STAT5A | AZD-1480 | Module 11 | TF |
SMAD3 | Ellagic acid | Module 10 | TF |
